Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients
Le Coz C, Nguyen DN, Su C, Nolan BE, Albrecht AV, Xhani S, Sun D, Demaree B, Pillarisetti P, Khanna C, Wright F, Chen PA, Yoon S, Stiegler AL, Maurer K, Garifallou JP, Rymaszewski A, Kroft SH, Olson TS, Seif AE, Wertheim G, Grant SFA, Vo LT, Puck JM, Sullivan KE, Routes JM, Zakharova V, Shcherbina A, Mukhina A, Rudy NL, Hurst ACE, Atkinson TP, Boggon TJ, Hakonarson H, Abate AR, Hajjar J, Nicholas SK, Lupski JR, Verbsky J, Chinn IK, Gonzalez MV, Wells AD, Marson A, Poon GMK, Romberg N. Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. Journal Of Experimental Medicine 2021, 218: e20201750. PMID: 33951726, PMCID: PMC8105723, DOI: 10.1084/jem.20201750.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgammaglobulinemiaB-LymphocytesCell DifferentiationCell LineChildChild, PreschoolChromatinDendritic CellsFemaleGene Expression Regulation, DevelopmentalHEK293 CellsHematopoiesisHematopoietic Stem CellsHumansInfantLymphopoiesisMaleMutationPrecursor Cells, B-LymphoidProto-Oncogene ProteinsStem CellsTrans-ActivatorsYoung AdultConceptsPioneer transcription factor PUPro-B cell lineHematopoietic cell fatePre-B cell transitionTranscription factor PUGene expression patternsHuman hematopoietic stemB cell developmentMyeloid cell differentiationBinds target DNAChromatin accessibilityDose-dependent roleCell fateGenomic sitesExpression patternsCell transitionCell developmentCell differentiationHematopoietic stemProgenitor cellsB cellsCell linesAgammaglobulinemia patientsMutationsTarget DNA